Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Generex provides guidance on safety of Ii-Key peptide vaccines » 09:07
03/19/20
03/19
09:07
03/19/20
09:07
GNBT

Generex

$0.00 /

+ (+0.00%)

Generex Biotechnology…

Generex Biotechnology provided guidance on their work to develop a peptide vaccine against the new coronavirus SARS-CoV-2 using the company's proprietary and patented Ii-Key immune system activation technology. This guidance is designed to assist third party groups and government agencies in their evaluation of potential vaccines against this pandemic SARS-CoV-2 virus. The patented NuGenerex Immuno-Oncology Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. In particular, the Ii-Key ensures potent activation of CD4+ T cells, which in turn facilitates antibody production to ward off infection. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation. Generex is working with our partners at EpiVax who have identified such protein fragments or epitopes to generate Ii-Key-SARS 2 peptide vaccines in collaboration with our peptide manufacturing partners. The peptides and Ii-Key are made from naturally occurring amino acids, ensuring an excellent safety profile for Ii-Key peptide vaccines.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Generex signs contract with EpiVax to develop Ii-Key peptide vaccines » 09:18
03/04/20
03/04
09:18
03/04/20
09:18
GNBT

Generex

$0.00 /

+ (+0.00%)

Generex Biotechnology…

Generex Biotechnology announced that the company has signed a contract with EpiVax to use their computational tools to predict epitopes that can be used to generate peptide vaccines against the nCOV-2019 corona virus using the patented NuGenerex Immuno-Oncology Ii-Key technology. EpiVax is a leader in computational vaccinology with expertise in epitope prediction, immune modulation, and dehumanized vaccine development. EpiVax has identified a number of "hotspots" in the amino acid sequences of the nCOV-2019 coronavirus proteins. Using the epitopes predicted by EpiVax, Generex will manufacture a series of synthetic amino acid peptides that mimic the epitopes of the virus and send them to China for testing. In collaboration with a team of researchers in China, Generex will test the reactivity of these peptides in blood samples that have been collected from patients who have recovered from COVID-19. Because these patients recovered from the coronavirus infection, their blood most likely contains immune cells and antibodies that recognize the peptides, proteins, and nucleic acids that represent antigenic epitopes of the virus. When the synthetic peptides are mixed with the blood samples, we can confirm that the sequences predicted by the EpiVax algorithms will be good vaccine peptides. Through a matrix assay that tests a series of peptides against the blood from recovered COVID-19 patients the team can select the best Ii-Key hybrid peptides to create a commercially viable vaccine that can proceed to human testing.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Hot Stocks
Generex provides clarification on stock dividends » 08:19
02/26/20
02/26
08:19
02/26/20
08:19
GNBT

Generex

$0.00 /

+ (+0.00%)

Generex Biotechnology…

Generex Biotechnology clarified certain information regarding its stock dividends consisting of two shares of Generex stock for every five shares held, and two shares of NuGenerex Immuno-Oncology for every five shares of Generex. These are two separate dividends. Information in our previous press release discussing the ex-dividend date and ramifications of the ex-dividend date apply only to the dividend of Generex shares. There is no Ex-Dividend Date for the NuGenerex Immuno-Oncology shares because those shares do not trade. The payment date for the NuGenerex Immuno-Oncology shares was February 24, and the market effective date is today.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Generex announces FINRA approval of corporate action, payment of dividends » 09:22
02/24/20
02/24
09:22
02/24/20
09:22
GNBT

Generex

$0.00 /

+ (+0.00%)

Generex Biotechnology…

Generex Biotechnology announced that FINRA has officially posted the Generex 2:5 stock dividends in Generex and NuGenerex Immuno-Oncology to the FINRA web site, and the dividends will be paid on Monday, February 24, 2020. Remember that anyone who sells their shares before the market close on the ex-date of February 25th will lose the dividend, which will be transferred to the buyer of your shares. Joe Moscato, President & CEO of Generex, said, "I would like to extend my congratulations and sincere thanks to our valued shareholders, because we can now officially declare that the stock dividends will be paid on Monday the 24th as FINRA has posted the approval of our corporate action on their web site. I would like to thank all of you for your patience and support of Generex throughout this process, which has delayed our plans for five months. We realize this delay has eroded share value, however, with the dividend paid, we are now we are poised for growth and success. With the dividend being paid next week, and our Generex S-1 registration statement filed, we can now execute fully on our plans. As a first step next week, we will be filing an S-1 for the spin out of NuGenerex Immuno-Oncology, with goal of listing directly onto the Nasdaq. With the S-1 funding, our subsidiaries can increase manufacturing, sales & marketing, and distribution of our revenue generating products. Our subsidiaries MediSource and Pantheon are already delivering sales growth of nearly 400% year over year, and we can now scale manufacturing to expand this growth. As Excellagen continues to gain approval from VAC committees in the VA system, we can expand the Olaregen sales force and implement our product line extension with Excellagen Aesthetics into the aesthetic dermatology market. We will turn on our public company MSO for orthopedic surgeons and podiatrists, and we will build NuGenerex Health in Arizona to deliver an integrated, multi-disciplinary diabetes management solution with our physician partners and continuing our efforts in diabetes, we will close on our acquisition of ALTuCELL, which is initiating human clinical trials of implanted cellular therapy using Altucaps for the treatment of Type I diabetes. We are excited about our opportunities to deliver exceptional value to our shareholders in 2020 as we achieve the success that we envisioned when we took over the company three years ago."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Generex to hold a conference call » 10:25
02/13/20
02/13
10:25
02/13/20
10:25
GNBT

Generex

$0.00 /

+ (+0.00%)

President & CEO…

President & CEO Moscato addresses the Coronavirus pandemic with Ii-Key Peptide Vaccines and provides a corporate update on a conference call to be held on February 13 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Generex to hold a conference call » 04:55
02/13/20
02/13
04:55
02/13/20
04:55
GNBT

Generex

$0.00 /

+ (+0.00%)

President & CEO…

President & CEO Moscato addresses the Coronavirus pandemic with Ii-Key Peptide Vaccines and provides a corporate update on a conference call to be held on February 13 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Generex to hold a conference call » 14:47
02/12/20
02/12
14:47
02/12/20
14:47
GNBT

Generex

$0.00 /

+ (+0.00%)

President & CEO…

President & CEO Moscato addresses the Coronavirus pandemic with Ii-Key Peptide Vaccines and provides a corporate update on a conference call to be held on February 13 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Generex declares new dividend record date of February 17 » 08:41
02/07/20
02/07
08:41
02/07/20
08:41
GNBT

Generex

$0.00 /

+ (+0.00%)

Generex Biotechnology…

Generex Biotechnology announced the successful completion of the FINRA review process for the dividend. After an exhaustive and long review, FINRA has determined that the original August 30 record date is too long ago to adequately track all the pay due bills from stock being bought and sold by investors, so a new record date of February 17th, 2020 has been established. This will insure everyone who has bought stock since August and retains the stock will receive the dividend not by way of a Pay Due Bill, but rather, directly from Generex. Those who sold stock after the original record date need not worry about anything as they were formally entitled to receive the dividend, but they would have had to transfer the dividend to the buyer of their shares. With the new February 17th record date being established, those who are entitled to receive the 5/2 stock dividend in Generex and the 5/2 stock dividend in NuGenerex Immuno-Oncology will receive it directly from the company. In addition, the pay date is now February 24th and ex-date is February 25th. If a shareholder sells the stock after the record date the pay due bill process will be in full effect and the shareholder will be required to transfer the dividend stock to the buyer. The ex-date rule in this situation is found in FINRA Rules Section 11140 (b)(2), which reads as follows: " In respect to cash dividends or distributions, stock dividends and/or splits, and the distribution of warrants, which are 25% or greater of the value of the subject security, the ex-dividend date shall be the first business day following the payable date."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Generex says NuGenerex subsidiaries working to address coronavirus » 08:26
02/06/20
02/06
08:26
02/06/20
08:26
GNBT

Generex

$0.00 /

+ (+0.00%)

Generex Biotechnology…

Generex Biotechnology announced that the company is working with third party groups and government agencies to reactivate the previously robust research and development to generate Ii-Key peptide vaccines against pandemic viruses. The patented NuGenerex Immuno-Oncology Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. In particular, the Ii-Key ensures potent activation of CD4+ T cells, which in turn facilitates antibody production to ward off infection. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation while maintaining absolute specificity of response. The peptides and Ii-Key are made from naturally occurring amino acids, ensuring an excellent safety profile for Ii-Key peptide vaccines. Also, there are many companies with existing facilities that can make clinical-grade synthetic peptide vaccines in hundred-kilogram quantities, providing a scalable, economically feasible rapid-response vaccine to pandemic viruses; a kilogram of Ii-Key peptide vaccine would be enough to vaccinate roughly 1 million people. Unfortunately, when these pandemics fade out, everyone forgets about them until the next one. When the SARS scare waned, we focused all of our resources on developing Ii-Key immunotherapeutic peptide vaccines for cancer. Generex has been on the forefront of immunotherapy using our proprietary Ii-Key peptide vaccine technology. NGIO has extensive experience with the design of viral and cancer vaccines. We designed a series of vaccine peptides for the potentially pandemic H5N1 avian influenza virus that were tested in over 120 volunteers as part of a Phase I trial. The vaccine peptides were safe, well tolerated, and generated a specific immune response as designed. In addition to the H5N1 study, peptides with the same Ii-Key modification have been used in multiple clinical trials in patients with early stage cancer, including breast and prostate cancers. To date, all Ii-Key peptide vaccine studies demonstrated excellent safety as well as specific and long-lasting immune responses. Avian influenza has recently been identified in animals in Wuhan, China so the Ii-Key-H5N1 vaccine, with human safety data is ready to be deployed in the clinical setting to inoculate people against another potential pandemic. Based on our experience from the H5N1 virus Ii-Key peptide vaccine program, we have developed a strategy to design, screen and identify vaccine peptides to any novel pathogenic virus within 5 months, and we are initiating efforts to develop a vaccine against 2019-nCOV.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Generex to host business news update conference call » 09:10
01/21/20
01/21
09:10
01/21/20
09:10
GNBT

Generex

$0.00 /

+ (+0.00%)

Conference call to…

Conference call to provide an update on the 2:5 Generex stock dividend, the 2:5 NuGenerex Immuno-Oncology (NGIO) stock dividend and the FINRA approval process will be held on January 21 at 9:30 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.